Answers are grounded in this paper and cite their sources.
Case report shows efgartigimod induces seroconversion and recovery in a patient with KLHL11-IgG cerebellitis, suggesting a new treatment option.
Background While immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, neurological immune-related adverse events (n-irAEs) associated with these agents are increasingly recognized. However, kelch-like protein-11(KLHL11)-IgG cerebellitis has not been reported as an n-irAE. Case presentation We report a case of a 53-year-old man with lung adenocarcinoma treated with tislelizumab who developed KLHL11-IgG cerebellitis. First-line immunotherapy, comprising intravenous methylprednisolone and immunoglobulin, failed to improved his symptoms. Subsequent administration of efgartigimod (10 mg/kg weekly for 4 doses) led to seroconversion of KLHL11-IgG and marked clinical recovery. Conclusion This is the first report of efgartigimod as a successful rescue therapy for isolated ICI-related KLHL11-IgG cerebellitis. These findings support efgartigimod as a promising treatment option for this condition.
No takes yet. Share an insight, caveat, or question.
Y et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: